---
reference_id: "PMID:28110826"
title: "Congenital Melanocytic Nevus Syndrome: A Case Series."
authors:
- Recio A
- Sánchez-Moya AI
- Félix V
- Campos Y
journal: Actas Dermosifiliogr
year: '2017'
doi: 10.1016/j.ad.2016.07.025
content_type: abstract_only
---

# Congenital Melanocytic Nevus Syndrome: A Case Series.
**Authors:** Recio A, Sánchez-Moya AI, Félix V, Campos Y
**Journal:** Actas Dermosifiliogr (2017)
**DOI:** [10.1016/j.ad.2016.07.025](https://doi.org/10.1016/j.ad.2016.07.025)

## Content

1. Actas Dermosifiliogr. 2017 Nov;108(9):e57-e62. doi: 10.1016/j.ad.2016.07.025. 
Epub 2017 Jan 19.

Congenital Melanocytic Nevus Syndrome: A Case Series.

[Article in English, Spanish]

Recio A(1), Sánchez-Moya AI(2), Félix V(3), Campos Y(4).

Author information:
(1)Unidad de Neonatología, Servicio de Pediatría, Complejo Hospitalario de 
Toledo, Toledo, España. Electronic address: aran.recio.linares@gmail.com.
(2)Servicio de Dermatología, Complejo Hospitalario de Toledo, Toledo, España.
(3)Unidad de Neonatología, Servicio de Pediatría, Complejo Hospitalario de 
Toledo, Toledo, España; Miembro investigador del Centro de Investigación 
Biomédica en Red de Enfermedades Raras (CIBERER U724), Madrid, España.
(4)Servicio de Anatomía Patológica, Complejo Hospitalario de Toledo, Toledo, 
España.

Congenital melanocytic nevus syndrome (CMNS) is the result of an abnormal 
proliferation of melanocytes in the skin and central nervous system caused by 
progenitor-cell mutations during embryonic development. Mutations in the NRAS 
gene have been detected in many of these cells. We present 5 cases of giant 
congenital melanocytic nevus, 3 of them associated with CMNS; NRAS gene mutation 
was studied in these 3 patients. Until a few years ago, surgery was the 
treatment of choice, but the results have proved unsatisfactory because 
aggressive interventions do not improve cosmetic appearance and only minimally 
reduce the risk of malignant change. In 2013, trametinib was approved for use in 
advanced melanoma associated with NRAS mutations. This drug, which acts on the 
intracellular RAS/RAF/MEK/pERK/MAPK cascade, could be useful in pediatric 
patients with CMNS. A better understanding of this disease will facilitate the 
development of new strategies.

Copyright © 2016 AEDV. Publicado por Elsevier España, S.L.U. All rights 
reserved.

DOI: 10.1016/j.ad.2016.07.025
PMID: 28110826 [Indexed for MEDLINE]